News

No strokes were experienced by the apixaban group, compared to 6 in the warfarin arm of the study.

Alcohol-related disorders and mood disorders accounted for 6.8% of avoidable emergency department visits.

The rates of viral rebound in people with long-term viral suppression on first-line regimens have become "extremely low," according to a study.

Preschool children presenting to emergency departments for wheezing did not benefit from the addition of azithromycin to symptomatic treatment.

While the national split is a significant jump from previously reported rates, the degrees of the success vary in different parts of the country, Barry S. Zingman, MD, Medical Director, AIDS Center, Montefiore Health System, told MD Magazine.

Netherland researchers tracked instances of the C. difficile therapy to as far back as 300 AD, in China.

A 10-year follow-up of patients with severe asthma finds persistent illness remains difficult to treat.

Subcutaneous monoclonal antibodies could change the stagnant scope of migraine treatment.

Cleveland Clinic physicians weigh in on their best methods for maintaining a good doctor-patient relationship.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of August 28.

An integrated care program successfully extended HCV treatment to patients not well served by traditional outreach efforts.

Researchers from Loyola Medicine retrospectively studied 100 vancomycin taper and pulse treatment patients treated for recurrent C. difficile infection over the span of 5 years.

Rivaroxaban plus aspirin showed a 31% reduction in major cardiovascular events for PAD patients.

Researchers found in data of 1,868 people that women who inject drugs are at a 38% greater risk of contracting HCV than men who inject drugs.

In a phase 2 trial, MDMA reduced PTSD in 68% of patients after a 12-months period.

The C3 inhibitor showed a 29% reduction in geography atrophy over a 1-year period.

It becomes only the second FDA-approved drug for the movement disorder, following valbenazine (Ingrezza) earlier this year.

The Section Head of Hepatology at the Cleveland Clinic discusses current issues in treating hepatitis, and what's still to come in possibly eradicating the disease.

Surveyed LGB adults also reported notably greater rates of heart conditions with more lesbian and bisexual women reporting strokes and heart attacks than heterosexual women, and more gay and bisexual men reporting chest pain related to heart disease than heterosexual men.

Despite receiving cardiac catheterization at lower rates than other weight categories, underweight patients were more likely to die, be readmitted, and have higher hospital costs.

The novel therapy showed sinus rhythm was present in 75% of patients after 1-year follow-up.

The US Food and Drug Administration has approved meropenem-vaborbactam as a treatment for adult patients with complicated urinary tract infections, including pyelonephritis.

The drug is the first treatment approved in the US for Chagas disease.

There are currently no known reports of patient harm for the 465,000 implanted devices in question, according to the FDA.

The genome wide association study found that a there may be a genetic link to how depression treatments work.

Merck's drug showed a 9% reduction in risk of major cardiovascular events in the REVEAL trial.

Yuko Nagaoki and colleagues at Hiroshima University compared the occurrence of hepatocellular carcinoma in HCV patients cured with direct acting antivirals and those given interferon therapy.

The drug was found to be most effective in its 150 mg and 300 mg doses, reducing cardiovascular events by 15% and 14%, respectively.

For every percentage of REM sleep loss, the risks of dementia increased 9%.